Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 3 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Lymphoid 1

Conditions

Breast Neoplasms 10Neoplasms 5Carcinoma, Non-Small-Cell Lung 4Pain, Postoperative 3Neurotoxicity Syndromes 3Melanoma 3Leukemia, Myeloid, Acute 3Brain Neoplasms 3Recurrence 2Ovarian Neoplasms 2Hemorrhage 2Chronic Pain 2Agnosia 2Vulvodynia 1Uterine Cervical Neoplasms 1Stomatitis 1Stomach Neoplasms 1Spinal Cord Neoplasms 1Small Cell Lung Carcinoma 1Skin Neoplasms 1Seizures 1Radiodermatitis 1Radiation Injuries 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Postoperative Complications 1Peripheral Nervous System Diseases 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Parathyroid Neoplasms 1Papillomavirus Infections 1Pancreatic Neoplasms 1

Interventions

Methotrexate 11Busulfan 11Cytarabine 10fludarabine 8Daunorubicin 8Cyclophosphamide 8fludarabine phosphate 7Whole-Body Irradiation 7Etoposide 7Tacrolimus 6Mitoxantrone 5Melphalan 5Idarubicin 5Thioguanine 4Peripheral Blood Stem Cell Transplantation 4Mycophenolic Acid 4Azacitidine 4thymoglobulin 3Radiotherapy 3Filgrastim 3Early Intervention, Educational 3Decitabine 3Cyclosporine 3Asparaginase 3Antilymphocyte Serum 3merphos 2luspatercept 2decitabine and cedazuridine drug combination 2Tretinoin 2Stem Cell Transplantation 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Myelodysplastic Syndromes × Sodium Chloride × Clear all
NCT04095858 2023-02-08

CATHY

Oncoimmune, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Phase 3 Terminated
11 enrolled 10 charts
LymphoidMyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡